Contineum Therapeutics Q3 EPS $(3.55), Cash Position $117.9M
$CTNM
Biotechnology: Pharmaceutical Preparations
Health Care
Contineum Therapeutics Q3 EPS $(3.55), Cash Position $117.9M
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/22/2024 | $32.00 | Outperform | Robert W. Baird |
SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut
Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Troy Ignelzi as an independent member of its Board of Directors and as Chair of the Audit Committee. Mr. Ignelzi brings nearly two decades of financial leadership and industry experience to Contineum's board. "I am extremely pleased to welcome Troy to the Contineum board. Troy's recent public markets experience, coupled with his proven t
- Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025 - Initial data readout planned for early 2026 - Neuropathic component of chronic pain linked to LPA1 activation Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced authorization of its Investigational New Drug (IND) application from the U.S. Food and Dr
Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to attend the following investor conferences during November 2024. Stifel 2024 Healthcare Conference, Monday, November 18, 2024, New York - Carmine Stengone, Contineum's President and CEO, will present at 4:10 p.m. ET. Jefferies 2024 London Healthcare Conference, Thursday, November 21, 2024, London
-Enrollment for PIPE-307 VISTA trial on track- -Strong cash position of $214 million at the end of Q3 expected to support operations through 2027- -Multiple potential clinical readouts in 2025- Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments in the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. "The third quarter of 2024 was focused on clinical exec
Robert W. Baird initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $32.00